Claritev Corporation (CTEV) Stock Price & Analysis
Claritev Corporation (CTEV) closed at USD 23.86 on Thursday, October 15, 2026, down 0.33% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 23.94; the Oct 15, 2026 session ranged USD 23.07–24.14 on volume of 196,153 shares. Market capitalization is $404.37M, with a 52-week range of USD 11.5–73.68 (NYQ). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CTEV.md
Key facts (CTEV)
- Last four reported quarters (through Jun 30, 2026): revenue $995M, net income -$283M (-28.5% margin), free cash flow -$17.9M (SEC filings).
- Analysts: Buy (mean 1.80 on a 1–5 scale) (5 analysts), mean target USD 46 (range 30–73).
- Total return with dividends: 1Y -57.8% vs S&P 500 +18.1%; 5Y -87.1% vs S&P 500 +85.1%.
- Next earnings: 2026-11-09, EPS estimate USD 1.71, revenue estimate $256M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CTEV)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.12B | $1.08B | $962M | $931M | $965M | $995M |
| Operating income | $386M | -$363M | $162M | -$1.39B | $28.8M | $32.5M |
| Net income | $102M | -$573M | -$91.7M | -$1.65B | -$284M | -$283M |
| EPS (diluted) | $6.40 | -$36.00 | -$5.69 | -$101.92 | -$17.30 | — |
| Free cash flow | $320M | $283M | $62.9M | -$10.5M | -$12.3M | -$17.9M |
| Operating margin | 34.5% | -33.6% | 16.8% | -149.4% | 3.0% | 3.3% |
| Net margin | 9.1% | -53.1% | -9.5% | -176.9% | -29.4% | -28.5% |
| Revenue growth | +19.2% | -3.4% | -10.9% | -3.2% | +3.7% | — |
| Cash + short-term investments | $185M | $334M | $71.5M | $16.8M | $16.8M | — |
| Total debt | $4.99B | $4.84B | $4.61B | $4.58B | $4.63B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CTEV)
P/S 0.4x · EV/EBITDA 37.5x · EV/Sales 5.1x · FCF yield -4.43% · Earnings yield -70.01% · Net debt $4.64B · EV $5.04B
Analysts (CTEV)
Consensus Buy (mean 1.80 on a 1–5 scale), 5 analysts; mean target USD 46 (low 30, high 73).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-21 | Barclays | Target raised | Overweight | $28 → $40 |
| 2026-08-12 | Wells Fargo | Target raised | Equal-Weight | $22 → $30 |
| 2026-08-10 | Citigroup | Target raised | Buy | $40 → $45 |
| 2026-08-10 | Canaccord Genuity | Target raised | Buy | $37 → $43 |
| 2026-07-21 | Canaccord Genuity | Target raised | Buy | $32 → $37 |
Total return (dividends reinvested) (CTEV)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -57.8% | -87.1% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -57.9% | -33.6% |
| Volatility (annualized) | 127.9% | 115.4% |
| Max drawdown | -81.1% (Oct 2025→Feb 2026) | -97.4% (Jun 2022→Dec 2024) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 23.86 |
|---|---|
| Change | ▼ 0.33% (down) |
| Previous Close | USD 23.94 |
| Open | USD 23.76 |
| Day Range | USD 23.07 – 24.14 |
| 52-Week Range | USD 11.5 – 73.68 |
| Volume | 196,153 shares |
| Market Cap | $404.37M |
| Exchange | NYQ |
Technical Analysis (CTEV)
Nexqual's technical model rates CTEV "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 31.99 (neutral) |
| vs SMA50 | Below (USD 31.7) |
| MACD | -2.17 (negative) |
Analyst Ratings (CTEV)
Wall Street analysts rate CTEV "Buy" based on 5 analysts, with a mean price target of USD 46 (range USD 30–73), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 46 |
| High Target | USD 73 |
| Low Target | USD 30 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (CTEV)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD 1.71 |
| Revenue Estimate | $256.13M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -2.94 vs est 1.33 ▼ miss |
| 2026-03-31 | USD -3.3 vs est 1.38 ▼ miss |
| 2025-12-31 | USD -3.19 vs est 0.85 ▼ miss |
| 2025-09-30 | USD -4.23 vs est -3.55 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (CTEV)
| Total Revenue | $994.67M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +6.60% |
| Gross Margin | +72.97% |
| Operating Margin | +12.80% |
| Profit Margin | -28.46% |
| Current Ratio | 1 |
| Total Cash | $14.37M |
| Total Debt | $4.69B |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$12.28M (-1.3% of revenue) |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (CTEV)
Nexqual rates Claritev Corporation's overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Mixed — Revenue +3.7% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 73%, operating 13% |
| Balance Sheet | Mixed — $14M cash vs $4.69B debt |
| Cash Flow | Weak — FCF negative: -$12M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Mixed — No data |
Ownership (CTEV)
| Insider Ownership | +7.26% |
|---|---|
| Institutional Ownership | +82.89% |
| Shares Outstanding | 16.95M |
| Float | 6.91M |
| Short % of Float | +9.58% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (CTEV)
Claritev Corporation is led by Travis S. Dalton (age 54), CEO, President & Chairman, per Nexqual as of October 16, 2026 at 05:20 UTC.
| CEO, President & Chairman | Travis S. Dalton (age 54) |
|---|---|
| Executive VP & CFO | Douglas M. Garis (age 40) |
| Executive VP & COO | Jerome W. Hogge (age 59) |
| Senior Vice President of Marketing & Communications | Melissa Humphrey |
Major Backers & Investors (CTEV)
Notable institutional backers of Claritev Corporation include H&F Corporate Investors VIII, Ltd., Ares Management LLC, Arini Capital Management Ltd, according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| H&F Corporate Investors VIII, Ltd. | 22.94% |
| Ares Management LLC | 10.99% |
| Arini Capital Management Ltd | 9.06% |
| Public Investment Fund | 7.56% |
| Beach Point Capital Management LP | 4.55% |
| CPV Partners, LLC | 2.92% |
| Prudential Financial, Inc. | 2.09% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.21% |
| Vanguard Group | 5.19% |
| Geode Capital | 1.33% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CARL | Carlsmed, Inc. | USD 13.95 | ▼ 3.59% |
| NRC | NRC Health | USD 21.11 | ▲ 4.66% |
| EVH | Evolent Health, Inc | USD 4.87 | ▲ 5.87% |
| SOPH | SOPHiA GENETICS SA | USD 7.29 | ▲ 2.82% |
| WEAV | Weave Communications, Inc. | USD 7.39 | ▲ 0.27% |
| PHR | Phreesia, Inc. | USD 11.04 | ▲ 2.7% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt